Lyell Immunopharma, Inc. (LYEL)
Nasdaq: LYEL · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2020
Filings
183 filings since 2017 beside 181 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by May 15, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 35 days after the quarter ended. The proxy statement was last filed Apr 24, 2026.
Filings a yearinsider forms included
1514252488981
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 8 times in the last 36 months, the newest Mar 9, 2026.Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest Jan 24, 2025.SEC letters: 13 in the last 36 months, the newest Jul 17, 2026.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
40 of 183 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.